The DOI matches its Crossref record; 23 of the 23 references it cites were found in a registry or an index.
Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial
Open accessAbstract
BACKGROUND: Tumor necrosis factor-alpha is present in arteries in giant cell arteritis. OBJECTIVE: To evaluate the efficacy of infliximab, an anti-tumor necrosis factor-alpha agent, in giant cell arteritis. DESIGN: Randomized, controlled trial. SETTING: 22 sites in the United States, the United Kingdom, Belgium, Italy, and Spain. PATIENTS: 44 patients with newly diagnosed giant cell arteritis that was in glucocorticosteroid-induced remission. INTERVENTION: Participants were randomly assigned in a 2:1 ratio to receive infliximab (5 mg/kg of body weight) or placebo. Sixteen patients were assigned to glucocorticosteroid plus placebo, and 28 patients to glucocorticosteroid plus infliximab. MEASUREMENTS: End points were measured through week 22, when an interim analysis resulted in early stopping of the planned 54-week trial. Primary end points were the number of patients who remained free of relapse through week 22 and adverse events. Secondary end points were time to first relapse, biomarkers, cumulative glucocorticosteroid dose, and the number of patients who remained relapse-free while the glucocorticosteroid dosage was tapered to 10 mg/d. RESULTS: Infliximab therapy did not increase the proportion of patients without relapse at week 22 compared with placebo (43% vs. 50%, respectively; difference, -7 percentage points [95% CI, -38 to 23 percentage points; P = 0.65), nor did it increase the proportion of patients whose glucocorticosteroid dosages were tapered to 10 mg/d without relapse (61% vs. 75%, respectively; difference, -14 percentage points [CI, -42 to 14 percentage points]; P = 0.31). The incidence of infection was 71% with infliximab and 56% with placebo (difference, 15 percentage points [CI, -14 to 45 percentage points]). LIMITATIONS: The sample was too small to rule out modest effects of infliximab and included only patients with a new diagnosis. Only one dose of infliximab was evaluated, and the study was terminated early. CONCLUSIONS: This trial is too small to draw definitive conclusions, but it provides evidence that using infliximab as maintenance therapy in patients in glucocorticoid-induced remission of newly diagnosed giant cell arteritis is of no benefit and may be harmful. If infliximab has benefit, it is unlikely to be great. ClinicalTrials.gov registration number: NCT00076726.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial
Hanauer, S. B., Feagan, B. G., Lichtenstein, G. R., Mayer, L. F., Schreiber, S., Colombel, J. F., Rachmilewitz, D., Wolf, D. C., Olson, A., Bao, W., et al. (2002) · The Lancet · doi:10.1016/s0140-6736(02)08512-4 · Cited by 4,169
The American College of Rheumatology 1990 criteria for the classification of giant cell arteritis
Hunder, G. G., Bloch, D. A., Michel, B. A., Stevens, M. B., Arend, W. P., Calabrese, L. H., Edworthy, S. M., Fauci, A. S., Leavitt, R. Y., Lie, J. T., et al. (1990) · Arthritis & Rheumatism · doi:10.1002/art.1780330810 · Cited by 2,539
Pocock, S. J., & Simon, R. (1975) · Biometrics · doi:10.2307/2529712 · Cited by 2,350
Maini, R. N., Breedveld, F. C., Kalden, J. R., Smolen, J. S., Davis, D., MACFARLANE, J. D., Antoni, C., Leeb, B. F., Elliott, M. J., Woody, J. N., et al. (1998) · Arthritis & Rheumatism · doi:10.1002/1529-0131(199809)41:9<1552::aid-art5>3.0.co;2-w · Cited by 1,623
Reich, K., Nestle, F. O., Papp, K., Ortonne, J.-P., Evans, R., Guzzo, C., Li, S., Dooley, L. T., & Griffiths, C. E. (2005) · The Lancet · doi:10.1016/s0140-6736(05)67566-6 · Cited by 1,045
Hanauer, S. B., Wagner, C. L., BALA, M. M., Mayer, L., Travers, S., Diamond, R. H., Olson, A. D., Bao, W., & Rutgeerts, P. J. (2004) · Clinical Gastroenterology and Hepatology · doi:10.1016/s1542-3565(04)00238-1 · Cited by 636
Glucocorticoid therapy in giant cell arteritis: Duration and adverse outcomes
Proven, A., Gabriel, S. E., Orces, C., O'Fallon, W. M., & Hunder, G. G. (2003) · Arthritis Care & Research · doi:10.1002/art.11388 · Cited by 612
Hoffman, G. S., Cid, M. C., Hellmann, D. B., Guillevin, L., Stone, J. H., Schousboe, J., Cohen, P., Calabrese, L. H., Dickler, H., Merkel, P. A., et al. (2002) · Arthritis & Rheumatism · doi:10.1002/art.10262 · Cited by 579
Self-citationJover, J. A., Hernández-García, C., Morado, I. C., Vargas, E., Bañares, A., & Fernández-Gutiérrez, B. (2001) · Annals of Internal Medicine · doi:10.7326/0003-4819-134-2-200101160-00010 · Cited by 518
Visual Manifestations of Giant Cell Arteritis: Trends and Clinical Spectrum in 161 Patients
González-Gay, M. A., García-Porrúa, C., Llorca, J., Hajeer, A. H., Brañas, F., Dababneh, A., González-Louzao, C., Rodriguez-Gil, E., Rodríguez-Ledo, P., & R. Ollier, W. E. (2000) · Medicine · doi:10.1097/00005792-200009000-00001 · Cited by 400
Cited by
Kleindorfer, D. O., Towfighi, A., Chaturvedi, S., Cockroft, K. M., Gutierrez, J., Lombardi-Hill, D., Kamel, H., Kernan, W. N., Kittner, S. J., Leira, E. C., et al. (2021) · Stroke · doi:10.1161/str.0000000000000375 · Cited by 3,237
Editor's Choice – Management of Descending Thoracic Aorta Diseases
Riambau, V., Böckler, D., Brunkwall, J., Cao, P., Chiesa, R., Coppi, G., Czerny, M., Fraedrich, G., Haulon, S., Jacobs, M. J., et al. (2017) · European Journal of Vascular and Endovascular Surgery · doi:10.1016/j.ejvs.2016.06.005 · Cited by 1,246
2018 Update of the EULAR recommendations for the management of large vessel vasculitis
Hellmich, B., Agueda, A., Monti, S., Buttgereit, F., de Boysson, H., Brouwer, E., Cassie, R., Cid, M. C., Dasgupta, B., Dejaco, C., et al. (2020) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2019-215672 · Cited by 1,200
Self-citationPolymyalgia rheumatica and giant-cell arteritis
Salvarani, C., Cantini, F., & Hunder, G. G. (2008) · The Lancet · doi:10.1016/s0140-6736(08)61077-6 · Cited by 767
Self-citationPolymyalgia Rheumatica and Giant Cell Arteritis
Ettlinger, R. E., Hunder, G. G., & Ward, L. E. (1978) · Annual Review of Medicine · doi:10.1146/annurev.me.29.020178.000311 · Cited by 687
Metadata
- Authors
- Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., Merkel, P. A., Weyand, C. M., Stone, J. H., Salvarani, C., Xu, W., Visvanathan, S., Rahman, M. U., & for the Infliximab-GCA Study Group*
- Venue
- Annals of Internal Medicine
- Publisher
- American College of Physicians
- Published
- 2007-05-01
- Volume
- 146
- Issue
- 9
- Pages
- 621-630
- ISSN
- 0003-4819
- 1539-3704
- OpenAlex
- W2159897707
- Cited by
- 563
- References
- 23
- FWCI
- 29.16
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial. https://app.cochat.ai/papers/10.7326/0003-4819-146-9-200705010-00004
- The paper
- Hoffman, G. S., Cid, M. C., Rendt-Zagar, K. E., Merkel, P. A., Weyand, C. M., Stone, J. H., Salvarani, C., Xu, W., Visvanathan, S., Rahman, M. U., & for the Infliximab-GCA Study Group*. (2007). Infliximab for Maintenance of Glucocorticosteroid-Induced Remission of Giant Cell Arteritis: A Randomized Trial. Annals of Internal Medicine. https://doi.org/10.7326/0003-4819-146-9-200705010-00004
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.